Potential of recombinant inorganic pyrophosphatase antigen as a new vaccine candidate against Baylisascaris schroederi in mice

Table 1 Experimental design of mouse vaccination and challenge

Trial and experimental group	Number of mice	0, 2, 4 wpv ^b	6-wpv ^b		1-wpc ^c	1-11 wpc ^c(80-dpc)
		Vaccination	Cytokine assay	Challenge	Larval recovery	Mortality
(Trial I)		(3 times per group)	(No. ^a)	(No. ^{a, d})	(No. ^a)	(No. ^a)
rBsc-PYP-1/FCA/PBS	30	rBsc-PYP-1 (FCA plus PBS)	10	20	10	10
FCA/PBS	30	FCA plus PBS	10	20	10	10
PBS	30	PBS	10	20	10	10
Trial and experimental group	Number of mice	0, 2, 4 wpv ^b	5-wpv ^b	6-wpv ^b	1-wpc ^c	1-12 wpc ^c (80-dpc)
		Vaccination	Challenge	Cytokine assay	Larval recovery	Mortality
(Trial II)		(3 times per group)	(No. ^a )	(No. ^{a, e} )	(No. ^{a, f} )	(No. ^a )
rBsc-PYP-1/FCA/PBS	30	rBsc-PYP-1 (FCA plus PBS)	20	10	10	-
FCA/PBS	30	FCA plus PBS	20	10	10	-
PBS	30	PBS	20	10	10	-

^a Number of mice involved in this assay.
^b Week(s) post-vaccination.
^c Week(s) post-challenge.
^d Number of remaining mice in each experimental group after “Cytokine assay” and used for the subsequent determinations of “Larval recovery” and “Mortality”.
^e Number of remaining mice in each experimental group after “Challenge”.
^f Number of mice derived from “Challenge”.

ISSN: 1297-9716